A single infusion of the experimental cell therapy ADI-001 led to reductions in disease activity for seven lupus patients in a clinical trial, according to preliminary data announced by its developer Adicet Bio. No serious side effects reported. “These preliminary results reinforce our belief that ADI-001 has the potential to transform the treatment landscape for […] The post Cell therapy ADI-001 reduces disease activity in lupus patients appeared first on Lupus News Today.
